MDMA and psilocybin are both part of psychedelic therapy but offer completely different experiences.
MDMA
3-4 hour experience characterized by warmth closeness and groundedness. Clinical protocol: 75-125 mg with optional booster dose. Best for relational trauma and PTSD. Mechanism: massive release of serotonin dopamine and oxytocin. MAPS research shows very high success rates for PTSD treatment.
Psilocybin
4-6 hours (up to 8) with perception shifts new perspectives and potential mystical experiences. Research shows promise for treatment-resistant depression OCD eating disorders and terminal anxiety.
Key difference
MDMA preserves the sense of self enabling focused emotional work. Psilocybin expands and challenges it bringing absolute perspective on life.
Note: Both substances are illegal in Israel. The therapeutic protocols referenced here apply to research contexts outside Israel under medical supervision.